Background: The hedgehog (HH) signaling pathway is abnormally activated in glioblastoma (GBM); thus, its downstream effector GLI1 may be a suitable target for the treatment of GBM. The aim of the present study was to evaluate the antitumor activities of a novel compound, FL34, in GBM through the inhibition of GLI1.
INTRODUCTION
Glioblastoma (GBM) is the most common and malignant type of central nervous system tumor in humans. [1, 2] At present, surgical resection followed by radiation and chemotherapy is the standard treatment for GBM. [3] Patients with GBM have a poor prognosis and a low long-term survival rate, despite efforts to identify the molecular basis of GBM tumorigenesis and develop novel cancer therapies. Furthermore, chemoresistance and recurrence are frequent. [3] Therefore, effective targeted therapeutic strategies are urgently required.
This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. The hedgehog (HH) signaling pathway may be initiated by the three HH ligands: sonic HH (SHH), Indian HH or Desert HH. Among them, SHH is the most widely expressed. The binding of HH ligands to patched (PTCH), a 12-pass transmembrane protein that inhibits smoothened (SMO), [4] relieves SMO from the suppression of PTCH. The stimulation of SMO results in the activation of downstream signaling targets, including transcription factors in the glioma-associated oncogene homolog family, for example, GLI1-3 and GLI target genes. [5] The HH pathway plays an important role in the control of cell proliferation, differentiation, angiogenesis, and tumor cell invasiveness. [6, 7] Based on the aberrant activation of the HH signaling pathway in multiple malignant tumors, including GBM, skin, lung and pancreatic cancer, the inhibition of the HH pathway by new therapeutic approaches has been investigated in various solid tumors. [8, 9] At present, HH modulators in clinical therapy have focused on the cell membrane receptor SMO, including GDC-0449 (vismodegib) and NVP-LDE225 (erismodegib). These drugs are selective, orally bioavailable SMO inhibitors that inhibit tumor growth and survival through antagonism of the SMO receptor. [10] However, resistance to SMO antagonists frequently emerges due to germline or acquired SMO mutations, [11] [12] [13] [14] or through SMO-independent means, including the activation of downstream GLI [14] [15] [16] or the upregulation of noncanonical GLI signaling. Furthermore, GLI1 has been reported to be hyperactivated in GBM. [16, 17] Thus, GLI1 may represent an attractive target for the development of antitumor drugs to treat GBM.
The present study showed the inhibitory effects of FL34 on GBM cell growth, invasion, and angiogenesis in vitro and subcutaneously transplanted, orthotopic xenograft models. Furthermore, FL34 decreased the transcriptional activity and expression of GLI1, resulting in the downregulation of GLI1 target genes, including B-cell lymphoma-2 (Bcl-2), vascular endothelial growth factor (VEGF), and matrix metalloproteinases (MMPs), without influencing the upstream SMO and cross-linked Ras/ERK and AKT signaling pathways. The results of the present study suggested that FL34 may be a potential antitumor candidate compound for GBM tumors.
METHODS
Cell lines and culture U-87 MG human brain tumor and HUVEC-T (HUVEC-T cells are SV40T-transformed HUVEC cells) cell lines were obtained from the Cell Center of the Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC. The T98G GBM cell line was obtained from Shanghai Xiangf Bio Company. U-87 MG cells were cultured in minimal essential media (MEM; Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.), 100 IU/mL penicillin, and 100 μg/mL streptomycin. Other cells were grown in Dulbecco's modified Eagle's medium (DMEM; Invitrogen; Thermo Fisher Scientific, Inc.,) supplemented with 10% FBS, 100 IU/mL penicillin, and 100 μg/mL streptomycin. The cells were maintained in a humidified atmosphere containing 5% CO 2 at 37°C. purity >98%). For the in vitro experiments, FL34 was dissolved in dimethyl sulfoxide (DMSO) and stored at 4°C until use. DMSO was used as the vehicle control in all in vitro experiments at a final concentration of 0.1%. For in vivo experiments, FL34 and TMZ were dissolved in a solution of 20% PEG400.
Drugs and compounds

Cell proliferation assay
Cell proliferation was analyzed by MTT assay. Cells were plated onto 96-well plates and cultured for 24 h. The cells were treated with various concentrations of FL34 in triplicate. At 72 h, 20 μl MTT (5.0 mg/mL) was added and the cells incubated for a further 4 h at 37°C in a 5% CO 2 atmosphere. The solution was removed and 150 μl DMSO was added. The optical density at 570 nm was measured using an ELISA reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The experiments were performed in triplicate.
Apoptosis assay
Apoptosis was analyzed using an Annexin V-FITC Apoptosis Detection kit (Nanjing KeyGen Biotech Co., Ltd., China). U-87 MG and T98G cells were plated onto 6-well plates and cultured for 24 h before FL34 was added at different concentrations. Following incubation for 72 h, the cells were harvested and washed with cold phosphate-buffered saline (PBS). Subsequent to suspension in binding buffer, the cells were stained with 10 μL FITC annexin V and 5 μL propidium iodide (PI) for 15 min. The cell samples were analyzed using an ACCURI C6 flow cytometry system (BD Biosciences, US).
Cell invasion assay
An invasion assay was performed using Transwell inserts containing polycarbonate filters with 8.0-μm pores. Matrigel (10 μL, 1.0 mg/mL) was added to the upper chamber. The cells (2 × 10 5 cells/well) were suspended in 200 μL 0.1% bovine serum albumin with or without different concentrations of FL34 and seeded into the upper chamber; 600 μL normal medium was placed in the lower chambers. Following 14 h incubation at 37°C in a 5% CO 2 atmosphere, the cells on the upper surface of the membrane were mechanically removed and the invading cells on the lower surface were fixed with methanol and stained with hematoxylin and eosin. The numbers of invasive cells in five random fields per membrane were counted at ×200 magnification (Olympus IX70, Japan). The experiment was performed in triplicate.
Tube formation assay
A total of 5000 HUVEC-T cells, treated or untreated with FL34, were seeded into a 96-well plate pre-coated with Matrigel. Following incubation at 37°C for 5 h, the cells were examined for capillary-like tube formation and photographed under a microscope (×100 magnification, Olympus IX70). All experiments were performed in triplicate. Orthotopic U-87 MG glioblastoma xenograft model and magnetic resonance imaging assessment of tumor volumes The heads of anesthetized male BALB/c/nu nude mice (Beijing Huafukang bioscience Co., Inc., China) were immobilized, and a 1-mm hole was drilled in the skull 1 mm posterior and 2 mm lateral to the bregma, on the right side. U-87 MG cells (1 × 10 6 cells in 5 μL PBS) were implanted intracerebrally 2.5 mm below the skull surface using a 26-gauge needle. Following injection, the skin was closed with surgical sutures. The animals were divided into three groups (control, FL34, and TMZ) with six mice per group. Treatments were started on the 5 th day postsurgery. FL34 and TMZ were administered orally at a dose of 30.0 mg/kg every day. FL34 was administered 6 days/week, and TMZ was successively administered for 5 days. The control mice received the vehicle alone.
In vivo efficacy evaluation using a xenograft model
MRI experiments were performed on a 7 Tesla 16 cm horizontal-bore magnet imaging system (PharmScan 70/16 US, Bruker, Switzerland). The animals were anesthetized with isoflurane (3% induction, 2% maintenance at 1 l/min in oxygen). A mouse surface head coil was used for signaling detection, and a 72-mm quadrature volume coil was used for transmission. Multislice T2-weighted image (T2WI) images were collected using a T2_Turbo RARE sequence with the following parameters: TR/TE, 2500 ms/35 ms; rare factor, 8; image size, 256 × 256; field of view, 25 mm × 25 mm; and slice thickness, 0.5 mm. Morphological T2WI images were used to assess tumor growth and calculate the tumor volumes. The tumor volumes were calculated from multiple MRI slice datasets using Philips DICOM Viewer 3.0 software ( Royal Dutch Philips Electronics Ltd., Amsterdam, The Netherlands).
GLI1 dual-luciferase assays
The luciferase reporter plasmid containing the GLI1-binding site (pGMGLI1-Lu) and the TK-Renilla luciferase plasmid (pGMR-TK) were purchased from Genomeditech Shanghai Co., Ltd. U-87 MG cells in 96-well plates were cotransfected with pGMR-TK and pGMGLI1-Lu using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.,) according to the manufacturer's protocol. At 24 h after transfection, the cells were treated with the indicated doses of FL34 and incubated for a further 48 h. Luciferase assays were performed using a dual luciferase reporter assay system (Promega Corporation; cat. no. E1960) following the manufacturer's protocol. The firefly luciferase values were normalized to the Renilla values.
Reverse transcription-quantitative polymerase chain reaction The Total RNA was isolated from U-87 MG and T98G cells treated with different concentrations of FL34 for 48 h and from U-87 MG xenograft tissues (3-4 randomly-selected tumors from U-87 MG xenograft mice from the control, 15.0, and 30.0-mg/kg FL34 groups) using TRIzol reagent (Takara, Dalian, China), following the manufacturer's protocol. The total RNA was reverse transcribed to cDNA using the SuperQuick RT MasterMix kit (CWBIO, Beijing, China). The quantitative polymerase chain reaction (qPCR) analyses were performed using UltraSYBR Mixture (CWBIO) on a 7900 Real-Time PCR system (Applied Biosystems) using the following primers: forward, 5'-CAGTGTGGGGACAGAAGGA-3' and reverse, 5'-CGGGGAGAAGAAAAGAGTGG-3' for GLI1; forward, 5'-CACATGGCCTCCAAGG-3' and reverse, and 5'-GGTTGAGCACAGGGTA-3' for GAPDH. The mRNA level of GLI1 was normalized to GAPDH, and the fold change of relative mRNA expression levels was determined using the 2 −ΔΔCt method.
Western blot analysis
Protein extraction and western blotting were performed as previously described. [18] Pooled tissues from 2 to 3 randomly-selected tumors from U-87 MG xenograft mice from the control, 15.0 mg/kg and 30.0 mg/kg FL34 groups, and U-87 MG and T98G cells treated with various concentrations of FL34 for 72 h, were lysed. For western blotting, the protein concentration was determined using the bicinchoninic acid method. Total proteins (50 μg) were separated through 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a nitrocellulose membrane by semi-wet electrophoresis. The membranes were blocked with Tris-buffered saline containing 1% Tween 20 and 5% skimmed dry milk, and incubated with dedicated primary antibodies (dilution, 1:1000; Cell Signaling Technology, Inc., Shanghai, China; Abcam Trading (Shanghai) Company Ltd., Shanghai, China.) overnight at 4°C. The samples were detected with a horseradish peroxidase-labeled goat anti-rabbit secondary antibody (dilution, 1:5000; Santa Cruz Biotechnology, Inc.,) for 1 h at room temperature, and developed using an enhanced chemiluminescence Western blot detection and analysis system (Applygen Technologies, Inc.). β-actin was used as a loading control.
Statistical analysis
Data were expressed as means ± standard deviation (SD). Differences between means were assessed using Student's two-tailed t-tests. P ≤ 0.05 was considered statistically significant. Microsoft Excel 2010 (Microsoft Corporation, Redmond, WA, USA) was used for the statistical analyses.
RESULTS
FL34 inhibition of glioblastoma cell proliferation
The growth inhibitory effect of FL34 was evaluated in U-87 MG and T98G cell lines using an MTT assay. 
FL34 inhibition of tube formation in HUVEC-T cells
The presence of blood vessels is associated with the malignancy and aggressiveness of glioma. [19] Thus, the present study examined the effects of FL34 on angiogenesis using a HUVEC-T cell tube formation assay. As presented in Figure 2ci and ii, the tube length was markedly decreased following treatment with 10.0 and 100.0 nmol/L FL34 for 5 h, whereas the proliferation of HUVEC-T cells was not influenced at the above concentrations (IC 50 : 11.65 ± 3.54 μmol/L at 5-h incubation). Table 1 and Figure 3a , b]. All animals gained weight during the experiment, indicating that the concentrations of FL34 used were well tolerated [ Table 1 ].
FL34 inhibition of U-87 MG tumor growth
To further prove the effect of FL34 in vivo, an intracranial glioma model in nude mice was generated. Mice were intracranially injected with U-87 MG cells. The mice were treated with FL34 and TMZ at 30.0 mg/kg. MRI was performed to evaluate the activity of FL34 on orthotopic U-87 MG tumor growth. The FL34-treated group exhibited marked shrinkage Simultaneous repression of GLI1 activity was confirmed by the reduction in the mRNA and protein expression levels of GLI1 ERK and AKT at the higher concentration (50.0 nmol/L in U-87 MG cells and 100.0 nmol/L in T98G cells), while no significant alterations in the total ERK and AKT levels were observed in U-87 MG cells [ Figure 5a ]. In the xenograft model, the expression of p-ERK was decreased compared with that in the control group only in the 30.0 mg/kg FL34-treated group, and there was little difference in the expression of p-AKT between the two FL34-treated groups and the control group. In addition, no significant alterations in the total ERK and AKT levels were observed in vivo in xenograft tumors [ Figure 5b ].
To further elucidate the mechanisms underlying the effects of FL34 on GBM cells, the expression of the principal proteins in the apoptotic cascade were examined. Consistent with the increase in the early apoptotic population, a dose-dependent increase in cleaved caspase 3 (c-caspase 3) level in FL34-treated U-87 MG and T98G cells was observed [ Figure 5c ]. Since Bcl-2 is strongly associated with cell survival [21] and is a downstream factor of the GLI1 oncoprotein, we analyzed Bcl-2 expression by western blotting, observing decreased protein expression in U-87 MG and T98G cells following Furthermore, crosstalk between HH and the AKT/ERK pathways has been reported. [20] Treatment with FL34 produced various effects on the p-ERK and p-AKT expression levels in GBM cells, as indicated in Figure 5a The level of FAK activation correlates with metastasis, and HH signaling reportedly plays a critical role in the induction of FAK phosphorylation. [22] Following a 72-h incubation with the aforementioned concentrations of FL34, p-FAK (Tyr397) and FAK expression levels were significantly downregulated in U-87 MG and T98G cells [ Figure 5e ]. Furthermore, the expressions of MMP9 and MMP2, downregulators of FAK, were also decreased following treatment with FL34 [ Figure 5e ]. The levels of the FAK and MMP proteins in tumors were also examined by western blotting; as shown in Figure 5f , the phosphorylation of FAK, MMP9, and MMP2 was significantly reduced in tumors of the FL34-treated groups compared to those in the control group.
To verify the effect of FL34 on VEGF expression, U-87 MG and T98G cells exposed to FL34 were analyzed for VEGF expression by western blotting. The expression of VEGF was significantly reduced in the FL34-treated GBM cells [ Figure 5e ]. The inhibitory effect of FL34 on VEGF expression was further confirmed in the U-87 MG tumors by western blotting. Similarly, the expression of VEGF in tumors treated with FL34 was much lower compared to that in the control [ Figure 5f ].
DISCUSSION
The frequent development resistance of cancer cells to SMO inhibitors in SMO-dependent or SMO-independent manners indicates the need for improved therapeutic targets to effectively block the HH signaling pathway. Currently, the antagonists targeting the HH pathway are mainly SMO inhibitors and inhibition of GLI1 is rarely reported. [23] GLI1 is hyperactivated in a panel of brain tumors including GBM [24] and is the final effector of the HH pathway. Therefore, inhibition of GLI1 may modulate targets downstream of or independently of SMO in HH-dependent tumors. The inhibition of GLI1 may overcome resistance to SMO inhibitors while avoiding adverse effects and may, thus, be a good therapeutic strategy.
This study investigated the effect of FL34 on the growth, angiogenesis, and invasion of GBM cells. Our results demonstrated that the FL34 inhibited the growth of U-87 MG and T98G cells. FL34 also inhibited tumor growth in the U-87 MG xenograft model. FL34 inhibited the transcriptional activity of GLI1 at 19.86 nmol/L, similar to GANT61, [25] resulting in the decreased expression of GLI1 at the mRNA and protein levels in vitro and in vivo in a xenograft model. Simultaneously, the expression of SMO was only marginally influenced by FL34 treatment. These findings suggested that FL34 inhibited GLI1 activation without influencing upstream canonical HH/SMO signaling in vitro and in vivo.
Crosstalk between GLI1 activation and other oncogenic signaling pathways including Ras/MEK/ERK and PI3K/AKT has been reported. [26, 27] Ras/ERK signaling acts upstream of GLI1 through the negative regulator SUFU [28] and ERK is likely to be the principal effector of this pathway. We evaluated the effects of FL34 on the phosphorylation and basal levels of ERK. We found that the FL34-mediated inhibition of GLI1 was not associated with ERK phosphorylation at a low concentration of FL34. In addition, PI3K/AKT inhibitors reportedly confer resistance to SMO agonists through the inactivation of GLI1, [29] supporting the idea that the PI3K/AKT pathway plays an important role in the regulation of GLI1 through crosstalk. Based on our results, the inactivation of GLI1 by FL34 was not due to the inhibition of AKT phosphorylation.
GLI transcription factors stimulate the expression of target genes that directly affect cell proliferation, including Bcl-2. [30] Bcl-2 is a pro-survival protein that is highly expressed in a subset of tumors. [21] Our data suggested that FL34 promoted apoptosis by decreasing the expression of Bcl-2 and increasing the expression of c-caspase 3. Thus, the effect of FL34 on apoptosis might be associated with the inhibition of GLI1.
GBM rarely metastasize out of the central nervous system, and local invasion is the primary means of tumor progression. Hence, more invasive GBM behavior is frequently correlated with a poorer patient prognosis. [31] SHH is positively associated with the phosphorylation of FAK at Tyr397. FAK serves an important role in invasion by regulating the expression of MMP2 and MMP9, which are critical glioma invasion-mediating factors. [32, 33] We demonstrated that FL34 inhibited the invasion of GBM. Furthermore, FL34 suppressed the phosphorylation of FAK and downregulated the expression of MMP2 and MMP9 in vitro and in vivo. These results suggested that the effect of FL34 on invasion might be due to the inhibition of FAK/MMPs, which might be linked to GLI1.
GLI1 regulates the expression of target genes associated with angiogenesis, including VEGF. [34, 35] The results of the present study demonstrated that FL34 inhibited vessel formation in HUVEC-T cells and downregulated VEGF expression in GBM cells and tumors in the xenograft model. Those results suggested that FL34 may exert anti-angiogenic effects through the inhibition of VEGF, which may be regulated by GLI1.
In addition, FL34 could be effective in other brain tumors with high GLI1 expression. The reported downregulation of GLI1 by the GLI1 inhibitor GANT61 or siRNA could increase the sensitivity of glioma cells to TMZ; [36, 37] therefore, FL34 may enhance the anti-tumor effect of TMZ. Their combined use might provide insights into therapeutic strategies for GBM and other types of gliomas.
CONCLUSIONS
The results of this study demonstrated that FL34 was able to inhibit the proliferation and invasion of GBM cells, suppress the formation of blood vessels, and inhibit the growth of GBM in a xenograft model by influencing the expression of Bcl-2, FAK/MMPs, and VEGF and mediated by the inactivation of GLI1 without affecting multiple upstream and cross-linked oncogenic signaling pathways.
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